Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III studyVolker Moebus, Christian Jackisch, Hans-Joachim Lueck, et al.
ESMO Open|November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trialMatteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
Breast Cancer Research : BCR|December 11, 2012
The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort studyKerstin Rhiem, Christoph Engel, Monika Graeser, et al.
Cancers|March 6, 2021
Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic ScoresKerstin Riecke, Volkmar Müller, Rudolf Weide, et al.
Journal of Cancer Research and Clinical Oncology|September 28, 2013
Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR studyNicolai Maass, Nadia Harbeck, Christoph Mundhenke, et al.
Plos One|October 12, 2012
Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancerAntonia Sophie Wenners, Keyur Mehta, Sibylle Loibl, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2011
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancerGunter von Minckwitz, Kathrin Schwedler, Marcus Schmidt, et al.
Cancers|October 1, 2020
Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain MetastasesElena Laakmann, Isabell Witzel, Tanja Neunhöffer, et al.
Anti-Cancer Drugs|March 16, 2019
A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)Joachim Bischoff, Jana Barinoff, Christoph Mundhenke, et al.
Lancet (London, England)|May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trialsJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
Pageof 10